Reports Q4 revenue $281.62M, consensus $293.59M. The company said, “Our fiscal 2026 demonstrated the resilience of our business model in a challenging consumer backdrop. Our diversified portfolio of leading brands with deep consumer heritage supports a durable financial profile and drives strong, growing free cash flow. In fiscal 2026, this resulted in $246.4 million of free cash flow driven by continued strength that included strong growth for Fleet, Dramamine, and Hydralyte in our Gastrointestinal category, which helped partially offset the impacts of limited eye care production as well as fourth quarter shipping disruptions in the Middle East.”
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PBH:
- Prestige Consumer price target lowered to $65 from $77 at Oppenheimer
- Is PBH a Buy, Before Earnings?
- Prestige Consumer Healthcare: Accretive Breathe Right Acquisition Reinforces Buy Rating and $86 Target
- Prestige Consumer Healthcare’s Breathe Right Acquisition: Strategic Expansion at an Attractive Valuation Supports Buy Rating
- Prestige Consumer to Acquire Breathe Right Brand Portfolio